Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ID Biochemical seeks to market infection test:

This article was originally published in Clinica

Executive Summary

ID Biochemical has filed for US FDA 510(k) clearance to market its rapid gene test for methicillin-resistant Staphylococcus aureus (MRSA), the cause of potentially fatal infection which is prevalent in hospitals. Data from clinical trials at four US hospitals showed that the Velogene Rapid MRSA test correctly identified 99.3% of samples when compared with conventional susceptibility tests and 100% when compared with results from the "gold standard" gene identification technology, PCR. Based on the Vancouver, British Columbia company's Cycling Probe Technology, the new test detects the MecA gene responsible for methicillin resistance.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT077656

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel